Pfizer
Rare Disease
Medical Affairs

ATTR-CM NEWS-BEAT

Cardiac Amyloidosis

Cardiac amyloidosis is a fatal and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. Although there are many different amyloid diseases, 2 types account for over 98% of all cardiac amyloidosis (CA): immunoglobulin light chain amyloidosis (AL) and Transthyretin Amyloid Cardiomyopathy (ATTR-CM)[1]



ATTR-CM: pathophysiology

Transthyretin is a tetrameric plasma protein responsible for transporting thyroxine and retinol-bound protein. It is primarily synthesized in the liver. Transthyretin tends to dissociate to dimers and monomers, which misassemble into fibrils and undergo deposition[2]



TTR, transthyretin

Point mutations or the effect of age can increase this tendency to dissociate, giving rise to the 2 clinical forms of ATTR: Hereditary (ATTRm, <10% of cases) and wild type (ATTRwt, >90% of cases) [2,3]. The most prevalent mutation in Israel is Ser77Tyr, among families of Jewish Yemenite descent [4,5].

Main Signs and symptoms of ATTR-CM[3,5]



Video Blog: "ATTR-CM - From Suspicion to Diagnosis"

Watch the highlights of the interview with Prof. Arthur Pollak, director of the cardiac amyloidosis program, Hadassah – Hebrew University of Jerusalem

Whom to SUSPECT? According to the ESC guidelines (2021)

Stay tuned for our upcoming "RED FLAGS" Newsletter!

Which signs and symptoms should raise your SUSPICION of Cardiac Amyloidosis?

Thank you for taking time to review this information.
Please reach out if you have any questions or would like to discuss further.

Ronnie Segev, DVM, Medical Affairs Scientist
Ronnie.Segev@pfizer.com
+972-54-5844854

Yoav Shetzer, PhD, Medical Affairs Scientist
yoav.shetzer@pfizer.com
+972-50-7628727

References:

1. Garcia-Pavia, Pablo et al. "Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases." European journal of heart failure vol. 23,4 (2021): 512-526. doi:10.1002/ejhf.2140
2. González-López, Esther et al. "Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope." Revista espanola de cardiologia (English ed.) vol. 70,11 (2017): 991-1004. doi:10.1016/j.rec.2017.05.036
3. McDonagh, Theresa A et al. "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure." European heart journal vol. 42,36 (2021): 3599-3726. doi:10.1093/eurheartj/ehab368
4. Waddington-Cruz, Márcia et al. "Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series." Orphanet journal of rare diseases vol. 14,1 34. 8 Feb. 2019, doi:10.1186/s13023-019-1000-1
5. Dori, Amir et al. "Ser77Tyr transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features." Annals of clinical and translational neurology vol. 10,4 (2023): 553-567. doi:10.1002/acn3.51741

EM-ISR-RDT-0009